Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447]
1 Charité Comprehensive Cancer Center, Berlin; Charité, Department of Hematology, Oncology and Tumor Immunology, Berlin; German Cancer Consortium (DKTK), Berlin. Electronic address: sebastian.ochsenreither@charite.de.
2 University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany.
3 Fondazione IRCCS San Raffaele Hospital, Milan, Italy.
4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
5 Glycotope GmbH, Berlin, Germany.
6 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
7 Charité Comprehensive Cancer Center, Berlin; German Cancer Consortium (DKTK), Berlin; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
8 Charité Comprehensive Cancer Center, Berlin; Charité, Department of Hematology, Oncology and Tumor Immunology, Berlin.